Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial.
Fabian ProftAnja WeißMurat TorgutalpMikhail ProtopopovValeria Rios RodriguezHildrun HaibelOlaf BehmerJoachim SieperDenis PoddubnyyPublished in: Therapeutic advances in musculoskeletal disease (2021)
A sustained clinical response was observed over the 10 years of the study with comparable response and drop-out rates between r-axSpA and nr-axSpA. Etanercept was well tolerated across the entire treatment period and showed a good safety profile with no new safety signals.